In the perspective of providing indications for the personalized uses of OU as a function of the molecular phenotypes of BC, we next evaluated the ERα-positive BC progression in relationship with the expression of the Na/K ATPase, which is the pharmacological target for OU and other CGs [13]. The gene discussed is ESR1; the disease is breast cancer.